The Manufacturers Life Insurance Company lowered its position in shares of Celcuity, Inc. (NASDAQ:CELC – Free Report) by 58.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,977 shares of the company’s stock after selling 39,686 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Celcuity were worth $2,927,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in CELC. Creative Planning acquired a new stake in shares of Celcuity in the second quarter valued at approximately $177,000. Rhumbline Advisers boosted its holdings in Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares during the last quarter. XTX Topco Ltd acquired a new position in Celcuity during the second quarter worth $169,000. Quantinno Capital Management LP grew its position in Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co grew its position in Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares in the last quarter. 63.33% of the stock is owned by institutional investors.
Celcuity Price Performance
Shares of CELC opened at $83.45 on Monday. The company has a market cap of $4.08 billion, a price-to-earnings ratio of -19.41 and a beta of 0.19. Celcuity, Inc. has a 1-year low of $44.42 and a 1-year high of $151.02. The company’s fifty day simple moving average is $92.98 and its 200 day simple moving average is $106.20. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. Stifel Nicolaus cut their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Citigroup restated a “market outperform” rating on shares of Celcuity in a report on Monday, August 17th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $155.00 target price on shares of Celcuity in a report on Friday, August 14th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $154.55.
Check Out Our Latest Stock Report on Celcuity
About Celcuity
Celcuity, Inc is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.
The company’s primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient’s tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.
Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs.
Read More
- Five stocks we like better than Celcuity
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
